BMP inhibitors and methods of use thereof

US10017516B2 · kind B2 · utility

Assignees

• The Brigham and Women's Hospital, Inc. · US
• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US

Inventors

• Asaf Alimardanov · Nanuet, US
• Gregory D. Cuny · Houston, US
• Gurmit Grewal · Natick, US
• Arthur Lee · San Jose, US
• John C. McKew · Ames, US
• Agustin H. Mohedas · Somerville, US
• Min-Jui Richard Shen · Boyds, US
• Xin Xu · Dongying, CN
• Paul B. Yu · Boston, US

Key dates

• Filing date: May 18, 2017
• Grant date: Jul 10, 2018
• Expiry date: May 18, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.